PME-1 suppresses anoikis, and is associated with therapy relapse of PTEN-deficient prostate cancers
A. Aakula, A. Isomursu, C. Rupp…·J. Westermarck
This study identifies PME-1 as a biomarker for aggressive PTEN-deficient prostate cancers by showing its role in suppressing anoikis.